09 Jun ADA2026: Survodutide Achieves 16.6% Average Weight Loss with Targeted Visceral Fat Reduction in Phase 3 SYNCHRONIZE-1 Trial
Phase 3 SYNCHRONIZE-1 trial data shows survodutide achieves up to 16.6% average weight loss with targeted visceral fat reduction and significant liver fat improvements — presented at ADA 2026....